BioAge Labs

BioAge Labs is a clinical-stage biotechnology company that applies insights from the biology of human aging to develop therapies for metabolic diseases such as obesity, type 2 diabetes and cardiovascular disease. The company frames age as a critical risk factor for cardiometabolic conditions and positions its research around identifying molecular mediators of aging-related decline that can be translated into druggable targets.

Its disclosed pipeline centers on two lead areas. BGE-102 is an orally dosed, CNS-penetrant NLRP3 inhibitor in Phase 1, aimed at blocking chronic inflammation associated with cardiovascular risk and metabolic dysfunction, with indications listed as cardiovascular risk and diabetic macular edema; the company anticipated full Phase 1 data in the first half of 2026 and reported positive Phase 1 hsCRP reduction data in April 2026. A second program targets the apelin receptor (APJ) as an "exercise mimetic" for obesity, in both oral once-daily and subcutaneous weekly formats, at lead optimization stage, with an IND submission anticipated by the end of 2026; preclinical models are described as showing doubled weight loss and restored body composition on an incretin background. Additional undisclosed discovery-stage programs address cardiometabolic indications. A third-party profile identifies azelaprag, an oral APJ agonist, as a lead asset intended for Phase 2 evaluation in combination with tirzepatide for obesity in older adults, though that source conflates azelaprag with the BGE-102 designation.

The company is headquartered at 5885 Hollis Street, Emeryville, California (third-party sources list Richmond, California), and maintains investor, careers, publications and podcast channels on its website.

Founding story

Third-party sources state BioAge Labs was founded in 2015 by Kristen Fortney (CEO) and Eric Morgen (COO), with early backing from Pear VC. Fortney's postdoctoral work at Stanford, in Stuart Kim's lab at the Stanford Genome Technology Center, focused on the genetics of extreme human longevity; the company grew out of her aim to combine genetic data and machine learning into a therapy discovery platform. Fortney holds a PhD in Medical Biophysics from the University of Toronto and was an Ellison Medical Foundation / American Federation for Aging Research fellow.

Business model

BioAge develops proprietary small-molecule and biologic therapeutic candidates in-house, funded by venture capital and public equity markets rather than product revenue. It supports a partnering function and, per a third-party profile, has entered clinical and research partnerships with large pharmaceutical companies.

Traction

The company has an asset in Phase 1 (BGE-102), reported positive Phase 1 hsCRP data in April 2026, and anticipates an IND for its APJ program by the end of 2026. It completed a Nasdaq IPO in September 2024 raising roughly $198 million and priced an upsized $115.0 million public offering in January 2026. Third-party sources report $294.0 million raised across four private rounds.

Latest developments

In January 2026 BioAge announced and then priced an upsized $115.0 million public offering. On April 21, 2026 it reported positive Phase 1 data for BGE-102, describing potential best-in-class reductions in hsCRP. Full Phase 1 data were expected in the first half of 2026, and an IND submission for the APJ program is anticipated by the end of 2026.